FORMULATIONS UNDERSTANDING CYCLIC COMPOUNDS. The present invention relates to the use of the cyclic compound of formula (I), wherein A, B independently at each occurrence are alkane-i, j-dil having k carbon atoms, and regardless of whether j is less than or equal to k and k is selected. from 1 to 10, wherein said alkane-i, dil-i (i) may comprise one or more double bonds； (ii) is optionally substituted； and / or (iii) comprises a cycle, wherein the total number of cycles wherein the cyclic sugars in said surface are selected from 0 to 47 and less than p (n + m)； X, Y independently at each occurrence are a biocompatible functional group comprising at least one oxygen atom or two sulfur atoms； n, m independently of each are selected from 0 to 20； p is selected from 1 to 10； n + m is equal to or greater than 1； and p (n + m) is selected from 3 to 30； wherein the components are capable of forming a complex with a primary protonated amino group and / or a protonated guanide group for the manufacture of the advanced pharmaceutical or diagnostic composition comprising a pharmaceutically or diagnostically active agent, said active agent comprising one or more primary and / or secondary protonated amino groups and / or protonated guanidium groups wherein (a) transmembrane and / or transmucosal delivery； (b) solubility of non-aqueous solvent ions and / or (c) stability of said active agent is improved.FORMULAÇÕES COMPREENDENDO COMPOSTOS CÍCLICOS. A presente invenção relata o uso do composto cíclico da fórmula (I), em que A, B independentemente em cada ocorrência são alcano-i, j-dil tendo k átomos de carbono, I e independente de j ser menor ou igual a k e k sendo selecionado de 1 a 10, em que o referido alcano-i, j-dil (i) pode compreender uma ou mais ligações duplas； (ii) é opcionalmente substituída； e/ou (iii) compreende um ciclo, em que o número total de ciclos sendo que os açúcares cíclicos no referido comosto são selecionados de 0 a 47 e menores de p (n+m)； X, Y independen
